Advance $20 million AstraZeneca expands its vaccine production partnership with Oxford Biomedica.

Read more: AstraZeneca and Oxford Biomedica expand collaboration on new coronary pneumonia vaccine
, AstraZeneca and Oxford Biomedica announced the further expansion of the new coronary pneumonia vaccine, AstraZeneca will pay Oxford Biomedica an initial fee of $20 million to meet the adenovirus COVID-19 vaccine AZD1222 up to 1000 liters of production capacity, at least 18 months of continuous supply.
that in May this year, the two companies signed an initial cooperation agreement.
agreement at the time provided for only one year of cooperation and 200 litres of vaccine production.
this cooperation is a further expansion of previous cooperation, it increases production capacity at the same time extended the cooperation time.
, the agreement is for a period of three years, with an additional 18 months of retention in addition to the required 18-month supply period.
as part of the agreement, Oxford Biomedica will retain capacity for AstraZeneca in three of the group's new 7,800-square-metre commercial manufacturing hub, Oxbox, within the first 18 months.
GMP facility is suitable for the production of virus vector vaccines and gene therapy vectors up to 1000 liters in size.
, which specializes in virus vectors, is expected to earn at least $47 million when it begins production of the AZD1222, The University of Oxford Biomedica said in a press release.
addition to its partnership with AstraZeneca, Oxford Biomedica has previously signed a five-year partnership with the UK Centre for Vaccine Manufacturing Innovation (VMIC).
for the partnership, Oxford Biomedica said two new production facilities within Oxbox would be operational within the next two months, much earlier than originally planned.
While the partnership with AstraZeneca means that Oxford Biomedica needs to invest in a number of new production facilities for this key project, Oxford Biomedica predicts that this will not have any impact on other partnerships already in the group, ensuring that other new partnerships are available or supported in the cell and gene therapy sector.
, AstraZeneca is working with researchers at Oxford University to develop a new crown vaccine with a global production capacity of nearly 3 billion doses.
news of the deal came as AstraZeneta also announced that it had launched a late-stage trial of the vaccine in the United States, which is scheduled to be conducted in 30,000 adults worldwide.
addition, AstraZeneta and Pfizer and BioNTech said they could obtain data on the new vaccine by October to ensure emergency approval from U.S. regulators.
reference source: Mylan, Bioconcut underinsorins competitors on price with launch of Lantus copycat.